New Dual-Action pill aims to tame type 2 diabetes

NCT ID NCT06144788

Completed Disease control Sponsor: Jeil Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests an experimental drug, JP-2266, in adults with type 2 diabetes. The drug works by blocking two proteins (SGLT1 and SGLT2) to help lower blood sugar. Participants receive either JP-2266 or a placebo for 12 weeks, and researchers measure changes in HbA1c, a key blood sugar marker.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JP-2266 (SGLT1/2 inhibitor)
What this could lead to: If successful, JP-2266 could offer a new oral option to help lower blood sugar in people with type 2 diabetes.
What could go wrong: This is an early phase 2 trial with a small number of participants. The drug may not prove more effective than existing treatments, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Show contact details

Locations

Severance Hospital

Seoul, Seodaemun-gu, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.